Lonza is the world's leading contract development and manufacturing organisation (CDMO) for biologics — producing monoclonal antibodies, cell and gene therapies, mRNA and small molecule APIs for pharmaceutical and biotech clients. Listed on SIX Swiss Exchange, Lonza occupies a unique position at the intersection of healthcare defensiveness and biotech cyclicality — its revenues track biopharmaceutical R&D investment and the commercial manufacturing needs of approved drugs.
Biologics CDMO: The Structural Growth Market
Lonza manufactures complex biological drugs (monoclonal antibodies, fusion proteins, ADCs) for pharmaceutical clients who outsource manufacturing to focus on drug discovery and commercialisation. Biologics now represent more than 50% of new drug approvals and are growing faster than small molecules. Lonza's Ibex biologic manufacturing facilities in Visp (Switzerland) and Portsmouth (US/UK) provide world-class mammalian cell culture capacity.
GLP-1: The Obesity Drug Manufacturing Boom
The extraordinary commercial success of GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro) for diabetes and obesity has created unprecedented demand for API manufacturing capacity. Lonza supplies peptide synthesis capabilities used in GLP-1 manufacturing and is expanding capacity to meet demand. The GLP-1 wave represents a multi-year manufacturing capacity build-out that benefits CDMOs with peptide synthesis expertise.
Cell & Gene Therapy: Long-Run Optionality
Lonza is a leading CDMO for cell and gene therapies (CAR-T, viral vectors, plasmid DNA) — complex personalised medicines with extraordinary growth potential. While still a small revenue contributor, the cell and gene therapy pipeline represents significant long-run optionality as these therapies move from clinical trials to commercial approval.
Biotech Funding Sensitivity
Lonza's CDMO revenues partially track biotech venture funding — when biotech funding is abundant, clinical-stage companies fund development programmes and outsource manufacturing to Lonza; when funding tightens (as in 2022–2023), some clinical programmes slow or pause. This sensitivity makes Lonza partially exposed to the biotech funding cycle despite its blue-chip pharmaceutical client base providing revenue stability.
Cycle Performance Summary
| Parameter | Value |
|---|---|
| Exchange | SIX Swiss Exchange |
| Ticker | LONN.SW |
| Primary Signal | Biotech funding + CDMO utilisation |
| Buy Threshold | Biotech funding contracts + utilisation < 70% |
| Sell Threshold | GLP-1 demand accelerates + biotech recovers |
| Biologics | Monoclonal antibodies — world leader |
| GLP-1 | Obesity drug manufacturing wave |
| Cycle Return (2020–2021) | +160% |
Track this signal in real time
Signycle Pro monitors Biotech Funding + CDMO Capacity and 16 other macro indicators — alerting you when the next cycle turns.
Join the Pro waitlist →